



## ANCCA NCCP Taskforce eMtg.22.2 (Feb 3) – Minutes of Meeting

Meeting Time (60 minutes)	From	To
<b>Pakistan</b>	12:00	13:00
<b>Sri Lanka</b>	12:30	13:30
<b>Nepal</b>	12:45	13:45
<b>Laos</b>	14:00	15:00
<b>Brunei, Malaysia, Philippines, Singapore</b>	15:00	16:00
<b>Japan, Korea</b>	16:00	17:00

### Participants (23 participants from 11 countries & organizations)

1. Brunei (BN): Dr. Babu Sukumaran, Dr. Ong Sok King / 2. Japan (JP): Dr. Tomohiro Matsuda, Dr. Manami Inoue, Dr. Sarah Abe, Laureline Gatellier, Ms. Akane Taminaga, Dr. Rei Haruyama, Dr. Sumiyo Okawa / 3. Korea (KR): Prof. Jeongseon Kim, Mr. Jong Soo Han / 4. Laos: Dr. Champadeng Vongdala / 5. Malaysia (MY): Dr. Siti, Dr. Nor Saleha binti Ibrahim Tamin, Dr. Suhana Yusak / 6. Nepal (NP): Dr. Kishore Pradhananga / 7. Pakistan: Dr. Aasim Yusuf / 8. Philippines (PH): Dr. Clarito U. Cairo / 9. Singapore (SG): Prof. William Hwang, Dr. Gillian Phua Li Gek, Mr. Koh Liang Kai / 10. Sri Lanka (SL): Dr. Harindra Jayasekara / 11. C/Can: Dr Aung Naing Soe

During the NCCP/ACAC meeting we welcomed several new members Harindra Jayasekara (Sri Lanka/Australia), Rei Haruyama and Sumiyo Okawa (National Center for Global Medicine Japan).

### 1. ACAC (Asian Code Against Cancer) report survey (Sarah/Sokking)

Sarah and Sokking gave an overview of the survey in preparation for the first manuscript. The survey file with an example from Brunei is attached. Please return by February 14<sup>th</sup>.

- a. Opinion about criteria to include in the Asian Code against Cancer
- b. Table overview of Asian country codes in comparison with the European Code against Cancer. Please check and modify as necessary. We hope the countries that have shared slides since the Satellite meeting in November will add relevant information for their countries (China, Laos, Nepal, Philippines) and (Bangladesh, Bhutan, Cambodia, Pakistan, Sri Lanka, and Turkey).
- c. Country-specific scientific evidence and publications.
- d. **ACTION for members**: For those who have not filled yet: please add relevant information in the attached word document, if possible by Feb. 14<sup>th</sup>, so we can move forward as core members, to work on the manuscript.



ACAC\_survey\_20  
220202.docx

### 2. Country snapshots Laos (Champadeng) and Nepal (Kishor)

- a. Champadeng gave an overview of the cancer control situation and timeline in Laos, with the recognition of cancer and establishment of a pathology unit in Laos. In 2017, the Cancer Center Act was enacted by the MoH in Laos. In 2022, Laos is establishing the first 5 years NCCP plan.
- b. Kishore provided a comprehensive overview to the burden of cancer in Nepal and highlighted risk factors unique to the region such as indoor and environmental air pollution, use of



chewing tobacco, use of insecticide/pesticides and chemical fertilizer, trans fat in food, arsenic in ground water, lack of use of PPE and screening programme, smoking in public places, salty pickles etc. These key points could be incorporated in the manuscript on journey towards developing Asian Code against Cancer

- c. **ACTION for members:** we plan to consult those of you who have not presented their country situation to share an overview of your country (Bangladesh, Bhutan, Cambodia, Pakistan, Sri Lanka and Turkey).
- 3. NCCP (National Cancer Control Program) (Tomohiro Matsuda)  
Tomohiro gave an update on the status of the NCCP project table and manuscript outline. The plan is to keep on working on the project by filling the current gaps.
- 4. ANCCA subcommittees (Laureline)  
Laureline gave an overview of the responses to the survey regarding participation in subcommittees. Thank you to those who have responded, if you have not yet completed the survey monkey poll, we look forward to hearing from you soon.  
[https://www.surveymonkey.com/r/ANCCA\\_SubCommittees\\_2022](https://www.surveymonkey.com/r/ANCCA_SubCommittees_2022)
- 5. Upcoming meeting (Laureline)  
Next ANCCA Regular quarterly e-meeting is planned on February 10<sup>th</sup>  
Next ANCCA monthly NCCP e-meeting is planned on March 3<sup>rd</sup>, we look forward to a long and meaningful collaboration with all of you.



Thank you all for the great participation!

